Breaking News

GENIXUS Launches KinetiX Syringe Platform to Address Shortages

Accelerates launch of Rocuronium Bromide Injection to address shortages in the U.S. market.

GENIXUS, a pharmaceutical company focused on acute and critical care medicines, launched its KinetiX syringe platform, Rocuronium Bromide Injection. The launch is in response to the recent natural disaster impacting Pfizer’s manufacturing site in Rocky Mount, NC, and the expected impact on the sterile injectables market as a result. KinetiX Rocuronium Bromide Injection is the second product in the syringe platform following GENIXUS’ launch of repackaged Propofol 10mL & 20mL RTA syri...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters